Vonoprazan for Helicobacter Pylori Eradication in Adolescents

Summary

The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).

Timeline

Start

2024-01-01

Primary completion

2024-08-01

Completion

2024-08-01

Outcome

Met primary endpoint

paper eradication of H. pylori was achieved in 93 (76.9%) of the ETT arm and in 106 (87.6%) of the VTT arm (p = 0.029). PMID 41131746 ↗

paper Fourteen days of VTT is superior to ETT for H. pylori eradication PMID 41131746 ↗

Publications

• Lashen SA, Shamseyea MM, Metwally RH, Abou-Farrag G, Elkaragy ES. Vonoprazan-Based Triple Therapy Versus Esomeprazole-Based Triple Therapy for H. pylori Eradication in Adolescents (VONTAPE): A Randomized, Double-Blind Controlled Trial. Helicobacter. 2025 Sep-Oct;30(5):e70083. doi: 10.1111/hel.70083.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Esomeprazole	Small molecule	20 mg	—
Comparator	Esomeprazole	Small molecule	40 mg	—
Subject	Vonoprazan	Other / unclassified	20 mg	—
Background	Amoxicillin	Other / unclassified	50 mg/kg	—
Background	Clarithromycin	Small molecule	20 mg/kg	—

Indications

No indication recorded.